Funding for this research was provided by:
National Key R&D Program of China (No.2021YFC2301900-2021YFC2301901)
National Special Research Program for Important Infectious Diseases (2017ZX10202102)
Received: 2 February 2022
Accepted: 1 February 2023
First Online: 15 February 2023
: The trial protocol (and other documents) was approved by the Ethics Committee of the First Affiliated Hospital of Zhejiang University (Zhejiang, China) in accordance with the Helsinki Declaration 1964 and its later amendments. Written informed consent was obtained from all patients. This study is registered with the China Clinical Trial Registry (ExternalRef removed; ChiCTR1900023184).
: All authors have approved this version of the manuscript.
: The authors declare no competing interests.